Access to a new treatment for ALS using a neuroprotective drug.
Intermediate-sized Expanded Access Protocol for CNM-Au8 in Amyotrophic Lateral Sclerosis (ALS).
This study is looking for people with ALS to try a new drug called CNM-Au8® that might help protect their nerve cells and improve their energy, with the hope of slowing down the progression of the disease.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10934384 on NIH RePORTER |
What this research studies
This research aims to provide individuals living with amyotrophic lateral sclerosis (ALS) across the United States, including those in remote areas, access to CNM-Au8®, a neuroprotective drug. The study focuses on addressing the energetic impairment of motor neurons, which is a key factor in ALS progression. By administering CNM-Au8, the research seeks to enhance energy levels in neurons, potentially slowing down the disease's progression. Participants will be monitored for safety and efficacy as part of this innovative treatment approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with amyotrophic lateral sclerosis (ALS) who are seeking new treatment options.
Not a fit: Patients with other neurological disorders or those not diagnosed with ALS may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could offer a new therapeutic option that may slow the progression of ALS and improve quality of life for patients.
How similar studies have performed: Previous studies have shown promising results with similar neuroprotective approaches in ALS, indicating potential for success with this treatment.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Andrews, Jinsy — Columbia University Health Sciences
- Study coordinator: Andrews, Jinsy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.